Artificial Intelligence: Fundamentals and Breakthrough Applications in Epilepsy
- PMID: 39554271
- PMCID: PMC11562289
- DOI: 10.1177/15357597241238526
Artificial Intelligence: Fundamentals and Breakthrough Applications in Epilepsy
Abstract
Artificial intelligence, machine learning, and deep learning are increasingly being used in all medical fields including for epilepsy research and clinical care. Already there have been resultant cutting-edge applications in both the clinical and research arenas of epileptology. Because there is a need to disseminate knowledge about these approaches, how to use them, their advantages, and their potential limitations, the goal of the 2023 Merritt-Putnam Symposium and of this synopsis review of that symposium has been to present the background and state of the art and then to draw conclusions on current and future applications of these approaches through the following: (1) Initially provide an explanation of the fundamental principles of artificial intelligence, machine learning, and deep learning. These are presented in the first section of this review by Dr Wesley Kerr. (2) Provide insights into their cutting-edge applications in screening for medications in neural organoids, in general, and for epilepsy in particular. These are presented by Dr Sandra Acosta. (3) Provide insights into how artificial intelligence approaches can predict clinical response to medication treatments. These are presented by Dr Patrick Kwan. (4) Finally, provide insights into the expanding applications to the detection and analysis of EEG signals in intensive care, epilepsy monitoring unit, and intracranial monitoring situations, as presented below by Dr Gregory Worrell. The expectation is that, in the coming decade and beyond, the increasing use of the above approaches will transform epilepsy research and care and supplement, but not replace, the diligent work of epilepsy clinicians and researchers.
© The Author(s) 2024.
Conflict of interest statement
The author(s) declared the following potential conflicts of interest with respect to the research, authorship, and/or publication of this article: Dr Kerr writes review articles for Medlink Neurology; has paid consulting agreements with SK Life Science, UCB, Janssen, Biohaven Pharmaceutical, and Cerebral Therapeutics; and has unpaid research agreements with UCB, GSK, Johnson & Johnson, Eisai, Radius Health, and Jazz Pharmaceuticals. Dr Kwan’s institution has received research grants from Eisai, Jazz Pharmaceuticals, Inc., UCB Pharma, and LivaNova; he/his institution has received consultancy fees from Angelini, Eisai, LivaNova, SK Life Sciences, and UCB Pharma. Dr Worrell is inventor of intellectual property developed at Mayo Clinic and licensed to Cadence Neuroscience Inc and NeuroOne Inc. He has received support from LivaNova, Medtronic, Cadence, NeuroOne, Neurilis. He is on scientific advisory boards of Cadence, LivaNova, and NeuroOne.
References
-
- Gebrael G, Sahu KK, Chigarira B, et al. Enhancing triage efficiency and accuracy in emergency rooms for patients with metastatic prostate cancer: a retrospective analysis of artificial intelligence-assisted triage using ChatGPT 4.0. Cancers (Basel). 2023;15(14):3717. doi:10.3390/cancers15143717 - PMC - PubMed
-
- Dougall GPT. Accessed January 2, 2024. https://dougallgpt.com/
Publication types
LinkOut - more resources
Full Text Sources
